Cambridge Investment Research Advisors
TNXP icon

Cambridge Investment Research Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-228
Closed -$8K – 3636
2024
Q4 		$8K Buy
+228
New +$4.74K ﹤0.01% 3447
2020
Q4 		– Hold
0
– -$24K – 2784
2020
Q3 		– Hold
0
– – – 2484
2020
Q2 		– Hold
0
– – – 2436

Other funds holding TNXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CIBC Asset Management
CIBC Asset Management Toronto, Ontario, Canada $40.9B AUM 35.96% 1-Year Est. Return

Cambridge Investment Research Advisors's TNXP Position: Q1 2025 in Review

Cambridge Investment Research Advisors sold out of Tonix Pharmaceuticals (TNXP) in Q1 2025, closing a stake of 228 shares — an estimated $8K sold.

Cambridge Investment Research Advisors first reported a position in TNXP in Q4 2024 and held it in 1 quarter. The position peaked at $8K in Q4 2024. 26 funds tracked by Wall St. Rank hold TNXP as of Q1 2025.

  • Cambridge Investment Research Advisors reported no remaining Tonix Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 228 Tonix Pharmaceuticals shares in Q1 2025, an estimated $8K.
  • Cambridge Investment Research Advisors first reported a position in Tonix Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Tonix Pharmaceuticals position peaked at $8K in Q4 2024.
  • 26 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2025, filed 22 Apr 2025.